



PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/567,157-Conf. #4222
Filing Date	June 1, 2006
First Named Inventor	Roberto Angelo Motterlini
Art Unit	1614
Examiner Name	A. A. Lewis
Attorney Docket Number	H0817.70003US00

Sheet 1 of 34

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	*	US-7,045,140	05-16-2006	Motterlini et al.	
	*	US-7,011,854	03-14-2006	Haas et al.	
	*	US-6,673,908	01-06-2004	Stanton, Jr.	
	*	US-6,645,938	11-11-2003	Oelting et al.	
	*	US-6,518,269	02-11-2003	Camden et al.	
	*	US-6,417,182	07-09-2002	Abrams et al.	
	*	US-6,350,752	02-26-2002	Glasky et al.	
	*	US-6,344,178	02-05-2002	Alberto et al.	
	*	US-6,338,963	01-15-2002	Glasky et al.	
	*	US-6,331,564	12-18-2001	Brugnara et al.	
	*	US-6,284,752	09-04-2001	Abrams et al.	
	*	US-6,251,927	06-26-2001	Lai et al.	
	*	US-6,242,432	06-05-2001	del Soldato	
	*	US-6,218,417	04-17-2001	Del Soldato	
	*	US-6,211,233	04-03-2001	Del Soldato	
	*	US-6,203,991	03-20-2001	Nabel et al.	
	*	US-6,177,471	01-23-2001	Menander et al.	
	*	US-6,066,333	05-23-2000	Willis et al.	
	*	US-6,060,467	05-09-2000	Buelow et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		EP-0076493-A2	04-13-1983	Dragoco Gerberding Co. GmbH		✓
		FR-2816212-A1	05-10-2002	Air Liquide Sante Int		✓
		GB-0111872.8-A	07-03-1968	Northwick Park Institute for Medical Research		
		GB-0227135.1-A	04-13-1994	Northwick Park Institute for Medical Research		
		GB-0227138.5-A	04-13-1994	Northwick Park Institute for Medical Research		
		GB-1107510-A	03-27-1968	Merck & Co. Inc		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to provide a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
Sheet	2	of	34
		Attorney Docket Number	H0817.70003US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear ³
	*	US-6,051,576	04-18-2000	Ashton et al.	
	*	US-6,040,341	03-21-2000	Del Soldato et al.	
	*	US-6,027,936	02-22-2000	Glasky	
	*	US-6,025,394	02-15-2000	Menander et al.	
	*	US-5,891,689	04-06-1999	Takle et al.	
	*	US-5,886,982	03-30-1999	Perrella et al.	
	*	US-5,885,621	03-23-1999	Head et al.	
	*	US-5,882,674	03-16-1999	Hermann et al.	
	*	US-5,861,426	01-19-1999	Del Soldato et al.	
	*	US-5,824,673	10-20-1998	Abrams et al.	
	*	US-5,811,463	09-22-1998	Legzdins et al.	
	*	US-5,801,184	09-01-1998	Glasky et al.	
	*	US-5,767,157	06-16-1998	Van Moerkerken	
	*	US-5,756,492	05-26-1998	Buelow et al.	
	*	US-5,700,947	12-23-1997	Soldato	
	*	US-5,670,664	09-23-1997	Kao et al.	
	*	US-5,664,563	09-09-1997	Schroeder et al.	
	*	US-5,659,027	08-19-1997	Spielvogel et al.	
	*	US-5,631,284	05-20-1997	Legzdins et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear ⁵	† ⁶
		Country Code ² -Number ³ -Kind Code ⁴ (if known)	MM-DD-YYYY			
		GB-2395431-A	05-26-2004	Northwick Park Institute for Medical Research		
		GB-2395432-A	05-26-2004	Northwick Park Institute for Medical Research		
		HU-211084-A2	12-30-1991	Brezo Magdolna et al.		
		HU-57595-A2	12-30-1991	Magdolna et al.		✓
		WO-85/04326-A1	10-10-1985	Biocompatibles Ltd		
		WO-91/01128-A1	02-07-1991	Eastman Kodak Co		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
Sheet	3	of	34
		Attorney Docket Number	H0817.70003US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	*	US-5,621,000	04-15-1997	Arena et al.	
	*	US-5,447,939	09-05-1995	Glasky et al.	
	*	US-5,350,767	09-27-1994	Hallberg et al.	
	*	US-5,312,816	05-17-1994	Spielvogel et al.	
	*	US-5,102,670	04-07-1992	Abraham et al.	
	*	US-5,086,060	02-04-1992	Haley et al.	
	*	US-5,010,073	04-23-1991	Kappas et al.	
	*	US-4,938,949	07-03-1990	Borch et al.	
	*	US-4,709,083	11-24-1987	Spielvogel	
	*	US-4,699,903	10-13-1987	Rideout et al.	
	*	US-4,668,670	05-26-1987	Rideout et al.	
	*	US-4,657,902	04-14-1987	Kappas et al.	
	*	US-4,649,151	03-10-1987	Dougherty et al.	
	*	US-4,613,621	09-23-1986	Hormann	
	*	US-4,189,487	02-19-1980	Klosa	
	*	US-3,829,504	08-13-1974		
	*	US-3,812,166	05-21-1974	Wiechert	
	*	US-3,694,232	09-26-1972		
	*	US-3,278,570	10-11-1966	Wilkinson et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		WO-91/01301-A1	02-07-1991	Eastman Kodak Co	
		WO-92/03402-A1	03-05-1992	Firmenich SA	
		WO-92/04905-A1	04-02-1992	Abraham et al.	
		WO-94/22482-A1	10-13-1994	Biorelease Tech Inc	
		WO-95/005814	03-02-1995	Johnson Matthey Public Limited Company	
		WO-95/009831	04-13-1995	Nicox S.A.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/567,157-Conf. #4222
				Filing Date	June 1, 2006
				First Named Inventor	Roberto Angelo Motterlini
				Art Unit	1614
				Examiner Name	A. A. Lewis
Sheet	4	of	34	Attorney Docket Number	H0817.70003US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	*	US-2,870,180	01-20-1959	Kozikowski et al.	
	*	US-2008-0026984	01-31-2008	De Matos et al.	
	*	US-2007-0219120	09-20-2007	De Matos et al.	
	*	US-2007-0207993	09-06-2007	Haas et al.	
	*	US-2007-0207217	09-06-2007	Haas et al.	
	*	US-2006-0233890	10-19-2006	Haas et al.	
	*	US-2006-0148900	07-06-2006	Haas et al.	
	*	US-2006-0147548	07-06-2006	Motterlini et al.	
	*	US-2006-0127501	06-15-2006	Motterlini et al.	
	*	US-2006-0115542	06-01-2006	Motterlini et al.	
	*	US-2005-0175555	08-11-2005	Stradi et al.	
	*	US-2005-0048133	03-03-2005	Pinsky et al.	
	*	US-2004-0228930	11-18-2004	Billiar et al.	
	*	US-2004-0214900	10-28-2004	Forbes et al.	
	*	US-2004-0143025	07-22-2004	Buelow et al.	
	*	US-2004-0131602	07-08-2004	Buelow et al.	
	*	US-2004-0067261	04-08-2004	Haas et al.	
	*	US-2004-0052866	03-18-2004	Otterbein et al.	
	*	US-2003-0219497	11-27-2003	Otterbein et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		WO-96/003125	02-08-1996	NeoTherapeutics	
		WO-96/009038	03-28-1996	William Harvey Research Limited	
		WO-97/16405-A1	05-09-1997	Nicox S.A.	
		WO-97/36615-A1	10-09-1997	President and Fellows of Harvard College	
		WO-97/37644-A1	10-16-1997	The General Hospital Corp.	
		WO-98/09618-A2	03-12-1998	Sangstat Medical Corporation	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ CITE NO.: Those application(s) which are marked with an single asterisk () next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ² Applicant's unique citation designation number (optional). ³ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	5	of	34
-------	---	----	----

Complete if Known

Application Number	10/567,157-Conf. #4222
Filing Date	June 1, 2006
First Named Inventor	Roberto Angelo Motterlini
Art Unit	1614
Examiner Name	A. A. Lewis
Attorney Docket Number	H0817.70003US00

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Page, Column, Lines, Where Relevant Passages Or Relevant Figures Appear	1 st
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
		WO-98/29115-A1	07-09-1998	Univ British Columbia		
		WO-98/38179-A1	09-03-1998	Glaxo Group Limited		
		WO-98/48848-A1	11-05-1998	Mallicknrodt Medical Inc et al.		
		WO-99/67231-A1	12-29-1999	Niox S.A.		
		WO-00/36113-A2	06-22-2000	Sangstat Medical Corporation		
		WO-00/56145-A1	09-28-2000	Univ James Cook et al.		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that patent was filed after 9/30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). See Kinds/Code of USPTO Patent Documents at www.uspto.gov or MPEP 301.04. Enter office that issued the patent. * SERIAL NO.: Serial number of the patent. * STATEMENTS: The inventor's statement, the inventor's oath or the statement of the Examiner must precede the serial number of the patent document. * KIND OF DOCUMENT by the appropriate symbols as indicated on the document under WPO/ISO Standard ST. If possible. * Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i> Application Number 10/567,157-Conf. #4222 Filing Date June 1, 2006 First Named Inventor Roberto Angelo Motterlini Art Unit 1614 Examiner Name A. A. Lewis Attorney Docket Number H0817.70003US00	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necess ary)					
Sheet	6	of	34		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant/Patents Or Relevant Figures Appear	†
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
		WO-00/56743-A1	09-28-2000	Anormed Inc		
		WO-00/61537-A2	10-19-2000	Nicox S.A.		
		WO-00/10613-A2	03-02-2000	The Regents of the University of Michigan		
		WO-01/12584-A2	02-22-2001	Nicox S.A.		
		WO-01/16359-A2	03-08-2001	Univ London et al.		
		WO-01/28545-A2	04-26-2001	NeoTherapeutics		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

EXAMINER: Initial if reference concise, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note nonconformity. Enclose copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(ii)) because that patent was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 301.04. * Error Office that issued the cited patent (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov. * Kind Code: The kind code of the claim of the patent must precede the serial number of the patent document. * Kind Number: The kind number by the appropriate symbols as indicated on the document under WPO Standard ST. It is possible. * Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i> Application Number 10/567,157-Conf. #4222 Filing Date June 1, 2006 First Named Inventor Roberto Angelo Motterlini Art Unit 1614 Examiner Name A. A. Lewis Attorney Docket Number H0817.70003US00	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	7	of	34		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
		WO-02/078584-A2	10-10-2002	Sangstat Medical Corp		
		WO-02/080923-A1	10-17-2002	Schmalz Hans-guenther et al.		
		WO-03/000114-A2	01-03-2003	Beth Israel Hospital et al.		
		WO-02/092072-A2	11-21-2002	Nicox S.A.		
		WO-03/067598-A2	08-14-2003	Koninklijke Philips Electronics N.V.		
		WO-03/072024-A2	09-04-2003	Beth Israel Hospital et al.		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

EXAMINER: Initial if reference concise, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not amended. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). See X(IX) of USPTO Patent Documents at www.uspto.gov or MPEP 901.6. * Enter Office that issued the document, by the two-letter standard ST.3. For Japanese documents, the indication of the year of the year of the Emperor must be indicated in place of the patent document number. For documents the appropriate symbols as indicated in the document under WIPO Standard ST-16 is possible. * Applicant is to place a check mark here if English language Translation is attached.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Column, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ¹ *Number*Kind Code ² (if known)				
		WO-2004/043341-A2	05-27-2004	University of Pittsburgh of The Commonwealth System of Higher Education		
		WO-2004/045598-A1	06-03-2004	Hemocorm Limited		
		WO-2004/045599-A1	06-03-2004	Hemocorm Limited		
		WO-2004/080420-A2	09-23-2004	Mota et al.		
		WO-2005/090400-A1	09-29-2005	The University Court of the University of Glasgow		
		WO-2006/012215-A1	02-02-2006	Flexitral, Inc.		
Examiner Signature	/Amy Lewis/			Date Considered	09/28/2010	

EXAMINER: Initial if reference concise, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and end examination. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(iii)) because that application was filed after 9/30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 301.4. * Enter Office that issued the application. * Enter the country of origin. * Enter the date of filing. * Enter the date of publication. * Enter the date of the year of the WIPO of the Emperor must precede the Serial number of the patent document. * Kind of document and the appropriate symbols as indicated on the document under MPEP 57.16, if possible. * Applicant is to place a check mark here if English document Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known Application Number 10/567,157-Conf. #4222 Filing Date June 1, 2006 First Named Inventor Roberto Angelo Motterlini Art Unit 1614 Examiner Name A. A. Lewis Attorney Docket Number H0817.70003US00	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	10	of	34		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Column Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
		WO-2007/073226-A1	06-28-2007	Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda		
		WO-2007/085806-A2	08-02-2007	Hemocomm Ltd et al.		
		WO-2008/003953-A2	01-10-2008	Hemocomm Ltd et al.		
		WO-2008/069688-A2	06-12-2008	Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda		
		WO-2008/130261-A1	10-30-2008	Alfama Investigacao E Desenvol et al.		
		WO-2009/013612-A1	01-29-2009	Alfama Investigacao E Desenvol et al.		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

EXAMINER: Initial if reference coincide, whether or not citation is in conformance with MPPE 609. Draw line through citation if not in conformance and not amended. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov/cpc/MPPE%20601A. ³ Error if citation that issued after the date of the cited document. ⁴ See Statement of the Prior Art, wherein the inventor(s) must indicate the year of the year of the grant of the Emperor mark preceded the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.16 is possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	11	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jour al, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		[No Author Listed] "supramolecule" IUPAC compendium of chemical terminology. Retrieved from the internet at www.iupac.org/goldbook/SO6153.pdf on May 8, 2006.	
		[No Author Listed] Biosis Chem Abstracts Database. Accession No. PREV200600414130. 2005. Otterbein et al., Cell Mol Biol (Nolisy-le-grand). 2005 Oct 3;51(5):433-40. Abstract.	
		[No Author Listed] Chemical Abstracts. 2002;137:119662. (FR2816212)	
		[No Author Listed] Chemical Abstracts. 2004;140:40075. (WO2004/043341)	
		[No Author Listed] Chemical Abstracts. 2004;141:270758. (Ryter et al.)	
		[No Author Listed] Chemical Abstracts. 2004;142:211995. (Stein et al.)	
		ABEL et al., Anionic halogenopentacarbonyls of chromium, molybdenum, and tungsten. J Chem Soc. 1963;2068-70.	
		ABEL et al., Carbonyl halides of manganese and some related compounds. J Chem Soc. 1959;Part 2:1501-5.	
		ABEL et al., Reaction of molybdenum carbonyl with various halides: a potassium etherate salt. Chem Indust. 1960;442.	
		ADKISON et al., Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. Epub 2005 Nov 15. Abstract only.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	12	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AKAMATSU et al., Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J. 2004 Apr; 18(6):771-2. Epub 2004 Feb 20.	
		ALESSIO et al., Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(II) Complexes: Synthesis, Structural Characterization, and Reactivity of Ru(CO)x(DMSO)4-xCl2 Complexes (x = 1-3). Inorg Chem. 1995;34(19):4722-34.	
		ALESSIO et al., Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(III) Complexes: Synthesis, Crystal Structure, and Reactivity of [(DMSO)2H][trans-RuCl4(DMSO-O)(CO)] and mer,cis-RuCl3(DMSO-O)2(CO). Inorg Chem. 1995;34(19):4716-21.	
		ALLANSON et al., Ultraviolet A (320-400 nm) modulation of ultraviolet B (290-320 nm)-induced immune suppression is mediated by carbon monoxide. J Invest Dermatol. 2005 Mar; 124(3):644-50.	
		ALLARDYCE et al., Development of organometallic (organo-transition metal) pharmaceuticals. Appl Organomet Chem. 2005;19:1-10.	
		AMERSI et al., Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology. 2002 Apr; 35(4):815-23.	
		ANDREADIS et al., Oxidative and nitrosative events in asthma. Free Radic Biol Med. 2003 Aug 1; 35(3):213-25. Review. Abstract only.	
		ANGELICI et al., Carboxamido carbonyl complexes of manganese(I). Inorg Chim Acta. Mar 1968; 2:3-7. Abstract only.	
		ANGELICI, Preparation, characterization, and reactions of the cis-Dihalotetracarboxylmanganate(I) anions. Inorg Chem. Aug 1964; 3(8):1099-1102.	
		AUJARD et al., Tridemethylisovaleral, a potent cytotoxic agent. Bioorg Med Chem. 2005 Nov 15; 13(22):6145-50. Epub 2005 Aug 1. Abstract only.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 50%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/567,157-Conf. #4222</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">June 1, 2006</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Roberto Angelo Motterlini</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">1614</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">A. A. Lewis</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	13	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Journ al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T ²
		BAGUL et al., Carbon monoxide protects against ischemia-reperfusion injury in an experimental model of controlled nonheartbeating donor kidney. Transplantation. 2008 Feb 27;85(4):576-81.	
		BANI-HANI et al., Modulation of thrombin-induced neuroinflammation in BV-2 microglia by carbon monoxide-releasing molecule 3. J Pharmacol Exp Ther. 2006 Sep;318(3):1315-22. Epub 2006 Jun 13.	
		BANNENBERG et al., Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide. Expert Opin Ther Pat. 2009 May;19(5):683-82. Review.	
		BARKOUDAH et al., The permissive role of endothelial NO in CO-induced cerebrovascular dilation. Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1459-65. Epub 2004 Jun 10.	
		BAUEROVÁ et al., Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys. 1999 Oct;18 Spec No:15-20. Review. Abstract only.	
		BEAL, Oxidatively modified proteins in aging and disease. Free Radic Biol Med. 2002 May 1;32(9):797-803. Review. Abstract only.	
		BEATY et al., An in vitro model for the in vivo mobilization of cadmium by chelating agents using 113Cd-NMR spectroscopy. Chem Res Toxicol. 1992;5:568-75. Abstract only.	
		BECKER et al., Age-related changes in antibody-dependent cell-mediated cytotoxicity in mouse spleen. Isr J Med Sci. 1979 Feb;15(2):147-50.	
		BECKER et al., NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol. 2001;1:13. Epub 2001 Dec 28.	
		BERMAN et al., Sensitization and catalysis of light-induced decarbonylation of aldehydes. J Am Chem Soc. 1963;85(24):4010-4013.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal; font-size: small;">Complete if Known</th> </tr> <tr> <td style="width: 30%; font-size: x-small;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td style="font-size: x-small;">Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td style="font-size: x-small;">First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td style="font-size: x-small;">Art Unit</td> <td>1614</td> </tr> <tr> <td style="font-size: x-small;">Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td style="font-size: x-small;">Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	14	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Jour, al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T ²
		BOISSIERE et al., Exercise and vasorelaxing effects of CO-releasing molecules in hypertensive rats. Med Sci Sports Exerc. 2006 Apr;38(4):652-9.	
		BOTROS et al., Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2772-8. Epub 2006 Jul 14.	
		BROOKS et al., The spoilage characteristics of ground beef packaged in high-oxygen and low-oxygen modified atmosphere packages. Proc. Reciprocal Meat Conference. University of Illinois at Urbana-Champaign. 2006.	
		BUNDGAARD et al., Pro-drugs as delivery systems. Pharm Int. 1981;2:136-40.	
		BUNDGAARD et al., Pro-drugs as drug delivery systems XX. Oxazolidines as potential pro-drug types for β -aminoalcohols, aldehydes or ketones. Intl J Pharm. Feb 1982;10(2):165-75. Abstract only.	
		BURGMAYER et al., Synthesis and structure of a 7-coordinate molybdenum carbonyl fluoride derivative - Et4N Mo(Co)2(S2cnet2)2f. Inorganic Chem. 1985;24:2224-30.	
		CAMPBELL et al., Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol. 2003 Oct;81(5):354-66.	
		CARROLL et al., Ligand abstraction in the reaction of aryl diazonium ions with some iron complexes containing coordinated cysteine, maleonitriledithiol, or triarylphosphine. Can J Chem. 1974;52:1914-22.	
		CEPINSKAS et al., Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice. Am J Physiol Gastrointest Liver Physiol. Jan 2008; 294:G184 - G191.	
		CHAKRAVORTY et al., Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect. 2003 Jun;5(7):621-7. Review. Abstract only.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222														
Filing Date	June 1, 2006														
First Named Inventor	Roberto Angelo Motterlini														
Art Unit	1614														
Examiner Name	A. A. Lewis														
Attorney Docket Number	H0817.70003US00														
Sheet	15	of	34												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		CHATTERJEE, Water-soluble carbon monoxide-releasing molecules: helping to elucidate the vascular activity of the 'silent killer'. Br J Pharmacol. 2004 Jun;142(3):391-3. Epub 2004 May 17.	
		CHLOPICKI et al., Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase. Cardiovasc Res. 2006 Jul 15;71(2):393-401. Epub 2006 Mar 22.	
		CHONSKI et al., Crown ethers in inorganic chemistry - preparation and characterization of group 6 pentacarbonyl hydroxides and fluorides. Inorganic Chem. 1975;14:1717-20.	
		CLARK et al., Measuring left ventricular function in the normal, infarcted and CORM-3-preconditioned mouse heart using complex admittance-derived pressure volume loops. J Pharmacol Methods. Mar-Apr 2009;59(2):94-9.	
		COBURN et al., Endogenous carbon monoxide production in man. J Clin Invest. 1963 Jul;42:1172-8.	
		COCEANI, Carbon monoxide in vasoregulation: the promise and the challenge. Circ Res. 2000 Jun 23;86(12):1184-6. Review.	
		COHEN et al., Diethylenetriamine-tetracarbonylmanganese(I). Inorg Chem. 1964;3(11):1641-42.	
		CONANT et al., Trimethylacetaldehyde and dimethylethylacetaldehyde. J Am Chem Soc. 1929;51(4):1246-55.	
		COTTON et al., Dimethyl- and diethyldithiocarbamate complexes of some metal carbonyl compounds. Inorg Chem. 2 Jun 1964;3:1398-1402.	
		COTTON et al., X-ray molecular structures of Mn(CO)5(O2CCF3) and Mn(CO)3(C5H5N)2(O2CCF3). Inorg Chem. 1981;20(4):1287-91.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	16	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DE BACKER et al., Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus. Naunyn Schmiedeberg's Arch Pharmacol. 2008 Nov;378(5):493-502. Epub 2008 Jun 18.	
		DE BACKER et al., Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. Gut. 2008 Mar;58(3):347-56. Epub 2008 Nov 20.	
		DE FILIPPO et al., Inductive effect in dithiocarbamate decomposition mechanism. J Org Chem. 1973;38(3):560-3.	
		DESMARD et al., A carbon monoxide-releasing molecule (CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival in an animal model of bacteraemia. FASEB J. 2009 Apr;23(4):1023-31. Epub 2008 Dec 18.	
		DESMARD et al., Carbon monoxide reduces the expression and activity of matrix metalloproteinases 1 and 2 in alveolar epithelial cells. Cell Mol Biol (Noisy-le-grand). 2005 Sep 30;51(4):403-8.	
		DI PASCOLI et al., Chronic CO levels have [corrected] a beneficial effect on vascular relaxation in diabetes. Biochem Biophys Res Commun. 2006 Feb 17;340(3):935-43. Epub 2005 Dec 27. Erratum in: Biochem Biophys Res Commun. 2006 Mar 14;342(3):1003.	
		DIAMANTIS et al., Preparation and structure of ethylenediaminetetraacetate complexes of ruthenium(II) with dinitrogen, carbon monoxide, and other pi-acceptor ligands. Inorg Chem. 1981;20:1142-50.	
		DOUGLAS et al., Preparation of some group VI fluorometal carbonyl derivatives. J Organometal Chem. 1974;65:65-9.	
		DREW et al., Synthesis, spectral properties, and reactions of manganese and rhenium pentacarbonyl phosphine and phosphite cation derivatives and related complexes. Inorg Chem. 1975;14(7):1579-84.	
		DROGE, Free radicals in the physiological control of cell function. Physiol Rev. 2002 Jan;82(1):47-95. Review.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal;">Complete if Known</th> </tr> <tr> <td style="width: 30%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	17	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DUCHÈNE et al., Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev. 1999 Mar 1;36(1):29-40.	
		EL-SAYED et al., Catalysis by crown ether complexes - part III effect of cation on the catalytic activity of crown ether - alkali metal halide complexes in the liquid phase oxidation of ethylbenzene. Egypt J Chem. 1979;22(1):23-8.	
		ELLIOTT et al., Nitric oxide: a regulator of mucosal defense and injury. J Gastroenterol. 1998 Dec;33(6):792-803. Review. Abstract only.	
		FAIRLAMB et al., Eta4-pyrone iron(0)carbonyl complexes as effective CO-releasing molecules (CO-RMs). Bioorg Med Chem Lett. 2006 Feb 15;16(4):995-8. Epub 2005 Nov 11.	
		FANG, Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol. 2004 Oct;2(10):820-32. Review. Abstract only.	
		FELDMANN et al., Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-96. Review.	
		FERRIER et al., FTIR spectrometric study of geometrical isomers of dicarbonyl ferrobisacetylacetonate influence of the counter cation. J Molec Struct. 1995;344(3):189-93.	
		FERRÁNDIZ et al., Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis. Ann Rheum Dis. 2008 Sep;67(9):1211-7. Epub 2007 Dec 6.	
		FISCHER et al., Methylpyridin-Chrom(O)-Tricarbonyl. Zeitschrift Fur Naturforschung Part-B-Chemie Biochemie Biophysik Biologie Und Verwandten Gebiete. 1959;14:736-7.	✓
		FISCHER et al., Über aromatenkomplexe von metallen. 37. zur aromatenkomplexbildung des pyridins mit chromhexacarbonyl. Chemische berichte-recueil. 1960;93:1156-61. English abstract provided.	✓

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449IPTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; font-weight: normal; font-size: small;">Complete if Known</th> </tr> <tr> <td style="width: 50%; font-size: x-small;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td style="font-size: x-small;">Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td style="font-size: x-small;">First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td style="font-size: x-small;">Art Unit</td> <td>1614</td> </tr> <tr> <td style="font-size: x-small;">Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td style="font-size: x-small;">Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	18	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FISCHER, Crystal structure of 1,4,7,10,13-pentaacetylpentadecane sodium bromide, C10H20BrNaO5. Zeitschrift für Kristallographie. 1996;2001:827-8.	√
		FIUMANA et al., Carbon monoxide mediates vasodilator effects of glutamate in isolated pressurized cerebral arterioles of newborn pigs. Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1073-9.	
		FORESTI et al., Reviewing the use of carbon monoxide-releasing molecules (CO-RMs) in biology: implications in endotoxin-mediated vascular dysfunction. Cell Mol Biol (Noisy-le-grand). 2005 Sep 30;51(4):409-23.	
		FORESTI et al., The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res. 1999 Dec;31(6):459-75. Review.	
		FORESTI et al., Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol. 2004 Jun;142(3):453-60. Epub 2004 May 17.	
		FRANGOGIANNIS et al., The inflammatory response in myocardial infarction. Cardiovasc Res. 2002 Jan;53(1):31-47. Review.	
		FRIEBE et al., Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996 Dec 16;15(24):6863-8.	
		FRIEBE et al., YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol. 1998 Dec;54(6):962-7.	
		FURCHGOTT et al., Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels. 1991;28(1-3):52-61.	
		GIBOREAU et al., Procedure for the preparation of pure dithiocarbamates. J Org Chem. 1994;59:1205-7.	
Examiner Signature /Amy Lewis/		Date Considered 09/28/2010	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is etched.

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(Use as many sheets as necessary)</i></p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222														
Filing Date	June 1, 2006														
First Named Inventor	Roberto Angelo Motterlini														
Art Unit	1614														
Examiner Name	A. A. Lewis														
Attorney Docket Number	H0817.70003US00														
Sheet	19	of	34												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GORDEUK et al., Carbonyl iron therapy for iron deficiency anemia. Blood. 1986 Mar;67(3):745-52.	
		GREENER, Now you're signaling, with gas: gasotransmitters open a window on biology and drug development. The Scientist. 2004;18(17):20.	
		GUO et al., Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1649-53. Epub 2004 Jan 2.	
		GÜNTHER et al., Carbon monoxide protects pancreatic beta-cells from apoptosis and improves islet function/survival after transplantation. Diabetes. 2002 Apr;51(4):994-9. MEDLINE Abstract.	
		HAAG et al., Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215. Review. Abstract only.	
		HADDLETON et al., [N-Alkyl-(2-pyridyl)methanimine]copper(I) complexes: characterisation and application as catalysts for atom-transfer polymerisation. 7 Dec 1998;1998(11):1799-1806. Abstract only.	
		HADDLETON et al., Atom transfer polymerization of methyl methacrylate mediated by alkylpyridylmethanimine type ligands, copper(I) bromide, and alkyl halides in hydrocarbon solution. Macromolecules. 1999;32(7):2110-19. Abstract only.	
		HADJIGOGOS, The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med. 2003 Mar;45(1):7-13. Review. Abstract only.	
		HENRICKS et al., Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther. 2001;14(6):409-20. Review. Abstract only.	
		HERRICK et al., Flash photolytic investigation of photinduced carbon monoxide dissociation from dinuclear manganese carbonyl compounds. Inorg Chem. 1984;23:4550-3.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	20	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HIEBER et al., Derivate des Mangancarbonyls mit schwefelorganischen Liganden. Chemische Berichte. 1966;99(7):2312-21.	✓
		HITCHON et al., Oxidation in rheumatoid arthritis. Arthritis Res Ther. 2004;6(6):265-78. Epub 2004 Oct 13. Review.	
		HOGG, Free radicals in disease. Semin Reprod Endocrinol. 1998;16(4):241-8. Review. Abstract only.	
		HOLMUHAMEDOV et al., Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998 Nov;275(5 Pt 2):H1567-76.	
		HOSGOOD et al., Application of nitric oxide and carbon monoxide in a model of renal preservation. Br J Surg. 2008 Aug;95(8):1060-7.	
		HUANG et al., Photolysis of the histidine-heme-CO complex. J Am Chem Soc. 1991;113:9141-4.	
		HUEBERS et al., Absorption of carbonyl iron. J Lab Clin Med. 1986 Nov;108(5):473-8.	
		IGNATEV et al., Reactivity of perfluoroalkyl halides towards nucleophiles. Russ J Electrochem. 1995;31(12):1235-9. Translated from Elektrokhimiya. 1995;31(12):1337-42.	✓
		JANDER et al., Neutralisationsanaloge reaktionen in essigsäureanhydrid. Zeitschrift für anorganische chemie. 1948;255:238-52. English abstract provided.	✓
		JELLUM et al., Quantitative determination of biologically important thiols and disulfides by gas-liquid chromatography. Analyst Biochem. 1969;31:339-47. Abstract only.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222														
Filing Date	June 1, 2006														
First Named Inventor	Roberto Angelo Motterlini														
Art Unit	1614														
Examiner Name	A. A. Lewis														
Attorney Docket Number	H0817.70003US00														
Sheet	21	of	34												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jour, al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T ²
		JOHANSEN et al., Spectrophotometric determination of the rates of hydrolysis of aldehyde-releasing pro-drugs in aqueous solution and plasma. Intl J Pharma. 1982 Dec;13(1):89-98. Abstract only.	
		JOHNSON et al., Metal carbonyls as pharmaceuticals? [Ru(CO)3Cl(glycinate)], a CO-releasing molecule with an extensive aqueous solution chemistry. Dalton Trans. 2007 Apr 21;(15):1500-8. Epub 2007 Mar 8.	
		JÓZKOWICZ et al., Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid Redox Signal. 2003 Apr;5(2):155-62.	
		KHARITONOV et al., Basis of guanylate cyclase activation by carbon monoxide. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2568-71.	
		KHARITONOV et al., Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Biochemistry. 1999 Aug 17;38(33):10699-706.	
		KRUEGER et al., Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004 Feb;140(2):218-25. Review.	
		KUIATE et al., Composition of the essential oil from leaves and flowers of Dichrocephala integrifolia (L.) O. Kuntze Chev. From Cameroon. Flavour and Fragrance J. 1999 Nov/Dec;14(6):419-20. Abstract only.	
		LAMBERT et al., O,O'-Diphenyldithiophosphatetetracarbonylmanganese(I) and related compounds. Inorg Chem. 1966;5(7):1287-9.	
		LAWTON et al., Myocardial oxygen consumption in the rabbit heart after ischemia: hyperpolarized arrest with pinacidil versus depolarized hyperkalemic arrest. Circulation. 1997 Nov 4;96(9 Suppl):II-247-52.	
		LEDGER, Carbon monoxide-releasing metal carbonyls: a new class of pharmaceuticals? Drug Disc Today. 2003;8:1096.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222														
Filing Date	June 1, 2006														
First Named Inventor	Roberto Angelo Motterlini														
Art Unit	1614														
Examiner Name	A. A. Lewis														
Attorney Docket Number	H0817.70003US00														
Sheet	22	of	34												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEE et al., Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. <i>Nat Med.</i> 2002 Mar;8(3):240-6.	
		LEVRAND et al., Controlled release of volatile aldehydes and ketones by reversible hydrazone formation - classical fragrances are getting dynamic. <i>Chem. Commun.</i> 2006;28:2965-7.	
		LI et al., Carbon monoxide protects PC12 cells from peroxynitrite-induced apoptotic death by preventing the depolarization of mitochondrial transmembrane potential. <i>Biochem Biophys Res Commun.</i> 2006 Apr 14;342(3):984-90.	
		LOFTSSON et al., Cyclodextrins in topical drug formulations: theory and practice. <i>Int J Pharm.</i> 2001 Aug 28;225(1-2):15-30. Review.	
		LOVELL et al., Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. <i>Paediatr Drugs.</i> 2004;6(3):137-46.	
		MAHMOUD et al., Potential anticancer agents. XVI. Isolation of bicyclopentadiene sesquiterpenoids from <i>Capsicodendron dinisii</i> . <i>J Nat Prod.</i> 1980 May-Jun;43(3):365-71. Abstract only.	
		MAINES, Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. <i>FASEB J.</i> 1988 Jul;2(10):2557-68. Review.	
		MARTINS et al., Induction of carbon monoxide in the donor reduces graft immunogenicity and chronic graft deterioration. <i>Transplant Proc.</i> 2005 Jan-Feb;37(1):379-81.	
		MATSUDA et al., Mediators of non-adrenergic non-cholinergic inhibitory neurotransmission in porcine jejunum. <i>Neurogastroenterol Motil.</i> 2004 Oct;16(5):605-12.	
		MATTES et al., Triply bridged thiobenzoato carbonyl manganates(I) and rhenates(I). The crystal and molecular structure of caesium tris(μ-thiobenzoato(S))bis(tricarbonyl rhenate). <i>J Organometal Chem.</i> 1979 Sept. 25; 178(1):191-6.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 30%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/567,157-Conf. #4222</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">June 1, 2006</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Roberto Angelo Motterlini</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">1614</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">A. A. Lewis</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	23	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MCMILLEN et al., Hydrocarbon bond dissociation energies. <i>Ann Rev Phys Chem.</i> 1982 Oct;33:493-532.	
		MEDER et al., Metallkomplexe mit biologisch wichtigen Liganden, XLII [1] carbonylmetallkomplexe mit anionen von mehrfunktionellen alpha-aminosäuren [Metal complexes with biologically important ligands], XLII [1] carbonyl metal complexes with anions of polyfunctional alpha-amino acids]. <i>Zeitschrift für Naturforschung</i> ;1986;1247-54. German language reference. English abstract provided.	√
		MEGIAS et al., The carbon monoxide-releasing molecule tricarbonyldichlororuthenium(II) dimer protects human osteoarthritic chondrocytes and cartilage from the catabolic actions of Interleukin-1beta. <i>J Pharmacol Exp Ther.</i> 2008 Apr;325(1):56-61. Epub 2008 Jan 14.	
		MIGUEL et al., Manganese(II) complexes with (tricyclohexylphosphonio)dithiocarboxylate as chelate and unidentate ligand. X-Ray crystal structure of fac-[Mn(CO)3(S2CP(C6H11)3)2(CIO4)H2O]. <i>J Chem Soc, Dalton Trans.</i> 1987;12:2875-80.	
		MIKULS et al., Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. <i>Drug Saf.</i> 2003;26(1):23-32. Review. Abstract only.	
		MONCADA et al., Nitric oxide: physiology, pathophysiology, and pharmacology. <i>Pharmacol Rev.</i> 1991 Jun;43(2):109-42.	
		MONCADA et al., The discovery of nitric oxide and its role in vascular biology. <i>Br J Pharmacol.</i> 2006 Jan;147 Suppl 1:S193-201.	
		MOORE et al., Brief inhalation of low-dose carbon monoxide protects rodents and swine from postoperative ileus. <i>Crit Care Med.</i> 2005 Jun;33(6):1317-26.	
		MORITA et al., Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. <i>Proc Natl Acad Sci U S A.</i> 1995 Feb 28;92(5):1475-9.	
		MORSE et al., Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. <i>J Biol Chem.</i> 2003 Sep 26;278(39):36993-8. Epub 2003 Jul 11.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	24	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MOTTERLINI et al., Characterization of vasoactive effects elicited by carbon monoxide-releasing molecules. Abstracts 8th Int'l Symposium on Mechanisms of Vasodilation. J Vasc Res. May 31-June 3, 2001:055.	
		MOTTERLINI et al., CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J. 2005 Feb;19(2):284-6. Epub 2004 Nov 19.	
		MOTTERLINI et al., Functional and metabolic effects of propionyl-L-carnitine in the isolated perfused hypertrophied rat heart. Mol Cell Biochem. 1992 Oct 21;116(1-2):139-45.	
		MOTTERLINI et al., Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs. 2005 Nov;14(11):1305-18. Review.	
		MOTTERLINI, Vasoactive properties of carbon monoxide-releasing molecules. Biomed Pharmacother. 2002;56(7):349-50.	
		MOYA et al., Metal carbonyl complexes containing heterocyclic nitrogen ligands: Part IX. MnBr(CO) ₃ (3,3',7,7'-R-2,2'-biquinoline) compounds. Polyhedron. 1 Mar 2002; 21(4):439-44. Abstract only.	
		MUNGRUE et al., From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand. 2003 Oct;179(2):123-35. Review. Abstract only.	
		MUSAMEH et al., Improved myocardial function after cold storage with preservation solution supplemented with a carbon monoxide-releasing molecule (CORM-3). J Heart Lung Transplant. 2007 Nov;26(11):1192-8.	
		MUSAMEH et al., Positive inotropic effects of carbon monoxide-releasing molecules (CORMs) in the isolated perfused rat heart. Br J Pharmacol. 2006 Dec;149(8):1104-12. Epub 2006 Oct 23.	
		NAGAI et al., Unusual CO bonding geometry in abnormal subunits of hemoglobin M Boston and hemoglobin M Saskatoon. Biochemistry. 1991 Jul 2;30(26):6495-503.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is effected.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222														
Filing Date	June 1, 2006														
First Named Inventor	Roberto Angelo Motterlini														
Art Unit	1614														
Examiner Name	A. A. Lewis														
Attorney Docket Number	H0817.70003US00														
Sheet	25	of	34												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Journ al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T²
		NAKAO et al., Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol. 2003 Oct;163(4):1587-98.	
		NAKAO et al., Protective effect of carbon monoxide in transplantation. J Cell Mol Med. 2006 Jul-Sep;10(3):650-71. Review.	
		NATHAN, Points of control in inflammation. Nature. 2002 Dec 19;26:420(6917):846-52. Review.	
		NDISANG et al., Modulation of the immunological response of guinea pig mast cells by carbon monoxide. Immunopharmacology. 1999 Jun;43(1):65-73.	
		NETO et al., Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol. 2004 Nov;287(5):F979-89. Epub 2004 Aug 3.	
		NITSCHKE et al., Properties of (trifluoromethanesulfonato)pentacarbonylmanganese(I) and -rhenium(I). Reactions in superacid solvents. Inorg Chem. 1985;24(13):1972-8.	
		NOBRE et al., Antimicrobial action of carbon monoxide-releasing compounds. Antimicrob Agents Chemother. 2007 Dec;51(12):4303-7. Epub 2007 Oct 8.	
		NUDELMAN et al., Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem. Jan 2001;36(1):63-74. Abstract only.	
		NUDELMAN et al., The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acylalkyl esters. J. Med. Chem.. 22 Jan 2005;48(4):1042-54. Abstract only.	
		NYDEGGER et al., New concepts in organ preservation. Transpl Immunol. 2002 May;9(2-4):215-25.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-------------------------------	-------------	----------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Complete if Known</th> </tr> <tr> <td style="width: 30%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	26	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		O'BRIEN et al., Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. <i>Crit Rev Toxicol.</i> 2005 Aug;35(7):609-62. Review.	
		OTTERBEIN et al., Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. <i>Nat Med.</i> 2003 Feb;9(2):183-90. Epub 2003 Jan 21.	
		OTTERBEIN et al., Heme oxygenase-1: unleashing the protective properties of heme. <i>Trends Immunol.</i> 2003 Aug;24(8):449-55. Review.	
		OZAWA et al., Leydig cell-derived heme oxygenase-1 regulates apoptosis of premeiotic germ cells in response to stress. <i>J Clin Invest.</i> 2002 Feb;109(4):457-67.	
		PAE et al., Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. <i>J Immunol.</i> 2004 Apr 15;172(8):4744-51.	
		PAINTNER et al., Synthesis and antimicrobial activity of tetrodecamycin partial structures. <i>Bioorg Med Chem.</i> 2003 Jul 3;11(13):2823-33. Abstract only.	
		PANKEY et al., Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. <i>Clin Infect Dis.</i> 2004 Mar 15;38(6):864-70. Epub 2004 Mar 1. Review.	
		PATEL et al., Preparation of (η5-cyclopentadienyl) and (η5-Methylcyclopentadienyl)Fe(CO)2Me cyclodextrin inclusion compounds and their subsequent ligand substitution reactions. Attempts at cyclodextrin mediated enantioselective ligand substitution. <i>J Organometal Chem.</i> 1997;547:103-112.	
		PELOSO et al., Expanding the armamentarium for the spondyloarthropathies. <i>Arthritis Res Ther.</i> 2004;8 Suppl 2:S36-43. Epub 2004 Jun 21.	
		PIANTADOSI, Biological chemistry of carbon monoxide. <i>Antioxid Redox Signal.</i> 2002 Apr;4(2):259-70. Review.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

²EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	27	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jour, al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T ²
		PNEUMATIKAKIS et al., Interactions of bis-[μ-chloro-chlorotricarbonylruthenium(II)] and poly-[μ-dichloro-dicarbonylruthenium(II)] with nucleotides. Inorg Chimica Acta. 1988;151:243-8.	
		QUICK et al., Pentacarbonylmanganese halides. In Inorganic Syntheses, Vol. 19. Duward F. Shriver, Ed. Inorganic Syntheses, Inc. 1979:158-63.	
		RATTAN et al., Mechanism of internal anal sphincter relaxation by CORM-1, authentic CO, and NANC nerve stimulation. Am J Physiol Gastrointest Liver Physiol. 2004 Sep;287(3):G605-11.	
		REHDER et al., 55Mn NMR characteristics of carbonylmanganese complexes with hetero-substituted dithioformato-, thioformamido- and thioformamide ligands [1]. Inorg Chim Acta. 1983;73:243-7. Abstract only.	
		REIMANN et al., Reactions of metal carbonyls. Part III. Steric and stereochemical limitations of higher substitution of manganese carbonyl bromide. J Chem Soc Dalton Trans. 1973;841-6. Abstract only.	
		RODELLA et al., Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radic Biol Med. 2006 Jun 15;40(12):2198-205. Epub 2006 Mar 20.	
		RUTKOWSKA-ZBIK et al., Theoretical density functional theory studies on interactions of small biologically active molecules with isolated heme group. J Comput Chem. 2007 Mar;28(4):825-31.	
		RYAN et al., Renal vascular responses to CORM-A1 in the mouse. Pharmacol Res. 2006 Jul;54(1):24-9. Epub 2006 Mar 9.	
		RYTER et al., Carbon monoxide in biology and medicine. Bioessays. 2004 Mar;26(3):270-80.	
		RYTER et al., Carbon monoxide: to boldly go where NO has gone before. Sci STKE. 2004 Apr 20;2004(230):RE6. Review.	
Examiner Signature		/Amy Lewis/	Date Considered
			09/28/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	28	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		RYTER et al., Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. <i>Physiol Rev.</i> 2006 Apr;86(2):583-650. Review.	
		RYTER et al., Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. <i>Mol Cell Biochem.</i> 2002 May-Jun;234-235(1-2):249-63. Review.	
		SACKS et al., Comparative bioavailability of elemental iron powders for repair of iron deficiency anemia in rats. Studies of efficacy and toxicity of carbonyl iron. <i>Am J Clin Nutr.</i> 1978 Apr;31(4):566-71.	
		SALAZAR-SALINAS et al., Molecular biosensor based on a coordinated iron complex. <i>J Chem Phys.</i> 2009 Mar 14;130(10):105101.	
		SANDBORN, Strategies for targeting tumour necrosis factor in IBD. <i>Best Pract Res Clin Gastroenterol.</i> 2003 Feb;17(1):105-17. Review.	
		SANDOUKA et al., Carbon monoxide-releasing molecules (CO-RMs) modulate respiration in isolated mitochondria. <i>Cell Mol Biol (Noisy-le-grand).</i> 2005 Sep 30;51(4):425-32.	
		SANDOUKA et al., Treatment with CO-RMs during cold storage improves renal function at reperfusion. <i>Kidney Int.</i> 2006 Jan;69(2):239-47.	
		SARADY et al., Carbon monoxide protection against endotoxemic shock involves reciprocal effects on iNOS in the lung and liver. <i>FASEB J.</i> 2004 May;18(7):854-6. Epub 2004 Mar 4.	
		SAWLE et al., Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. <i>Br J Pharmacol.</i> 2005 Jul;145(6):800-10.	
		SAWLE et al., Homocysteine attenuates endothelial haem oxygenase-1 induction by nitric oxide (NO) and hypoxia. <i>FEBS Lett.</i> 2001 Nov 23;508(3):403-6.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	29	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHMIDT et al., Manganese(II) and rhodium(III) pentacarbonyl(trifluoromethanesulfonate) complexes. In Inorganic Syntheses, Ed. Herbert D. Kaesz. Inorganic Syntheses, Inc. 1989:113-7.	
		SCHUBERT, The action of carbon monoxide on iron and cobalt complexes of cysteine. Carbon Monoxide on Iron and Cobalt Cysteine Complexes. 1933;55:4563-70.	
		SHAPIRO, Carbonyl-trapping therapeutic strategies. Am J Ther. 1998 Sep;5(5):323-53. Review.	
		SHIOHARA et al., Protective effect of carbon monoxide donor compounds in endotoxin-induced acute renal failure. Am J Nephrol. 2007;27(5):441-6. Epub 2007 Jul 12.	
		SILVER et al., Mossbauer studies on protoporphyrin IX iron (II) solutions containing sulphur ligands and their carbonyl adducts. Inorg Chimica Acta. 1984;9:279-83.	
		SJÖSTRAND, Endogenous formation of carbon monoxide in man under normal and pathological conditions. Scan J Clin Lab Invest. 1949;1:201-14.	
		SKATTEBØL et al., Synthesis of (±)-Lineatin, an aggregation pheromone component of Trypodendron lineatum. Acta Chem Scand B. 1985;39:291-304.	
		SONG et al., Carbon monoxide inhibits T lymphocyte proliferation via caspase-dependent pathway. J Immunol. 2004 Jan 15;172(2):1220-6.	
		SPECTOR, Review: Oxidative stress and disease. J Ocul Pharmacol Ther. 2000 Apr;16(2):193-201. Review. Abstract only.	
		SRISOOK et al., CO from enhanced HO activity or from CORM-2 inhibits both O2- and NO production and downregulates HO-1 expression in LPS-stimulated macrophages. Biochem Pharmacol. 2006 Jan 12;71(3):307-18. Epub 2005 Dec 2.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>			Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/567,157-Conf. #4222</td> </tr> <tr> <td>Filing Date</td> <td>June 1, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Roberto Angelo Motterlini</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>A. A. Lewis</td> </tr> <tr> <td>Attorney Docket Number</td> <td>H0817.70003US00</td> </tr> </table>		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Application Number	10/567,157-Conf. #4222															
Filing Date	June 1, 2006															
First Named Inventor	Roberto Angelo Motterlini															
Art Unit	1614															
Examiner Name	A. A. Lewis															
Attorney Docket Number	H0817.70003US00															
Sheet	30	of	34													

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		SRISOOK et al., Role of NO in enhancing the expression of HO-1 in LPS-stimulated macrophages. <i>Methods Enzymol.</i> 2005;396:368-77.		
		STAAL et al., The syntheses and coordination properties of M(CO)3X(DAB) (M = Mn, Re; X = Cl, Br, I; DAB = 1,4-diazabutadiene). <i>J Organometal Chem.</i> 1 May 1979;170(2):235-45. Abstract only.		
		STAGNI et al., A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits. <i>Br J Ophthalmol.</i> 2009 Feb;93(2):254-7. Epub 2008 Oct 31.		
		STANFORD et al., Carbon monoxide inhibits endothelin-1 release by human pulmonary artery smooth muscle cells. <i>Eur J Pharmacol.</i> 2004 Feb 23;486(3):349-52.		
		STANFORD et al., Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role. <i>Eur J Pharmacol.</i> 2003 Jul 25;473(2-3):135-41.		
		STEC et al., Heme oxygenase-1 induction does not improve vascular relaxation in angiotensin II hypertensive mice. <i>Am J Hypertens.</i> 2008 Feb;21(2):189-93. Epub 2008 Jan 3.		
		STEIN et al., Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. <i>J Mol Cell Cardiol.</i> 2005 Jan;38(1):127-34. Epub 2004 Dec 8.		
		STONE et al., Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. <i>Biochemistry.</i> 1994 May 10;33(18):5636-40.		
		SUN et al., Attenuation of leukocytes sequestration by carbon monoxide-releasing molecules: liberated carbon monoxide in the liver of thermally injured mice. <i>J Burn Care Res.</i> 2007 Jan-Feb;28(1):173-81.		
		SUN et al., CO-releasing molecules (CORM-2)-liberated CO attenuates leukocytes infiltration in the renal tissue of thermally injured mice. <i>Int J Biol Sci.</i> 2008 Jun 16;4(3):176-83.		

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 30%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/567,157-Conf. #4222</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">June 1, 2006</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Roberto Angelo Motterlini</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">1614</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">A. A. Lewis</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">H0817.70003US00</td> </tr> </table>		Complete if Known		Application Number	10/567,157-Conf. #4222	Filing Date	June 1, 2006	First Named Inventor	Roberto Angelo Motterlini	Art Unit	1614	Examiner Name	A. A. Lewis	Attorney Docket Number	H0817.70003US00
Complete if Known																	
Application Number	10/567,157-Conf. #4222																
Filing Date	June 1, 2006																
First Named Inventor	Roberto Angelo Motterlini																
Art Unit	1614																
Examiner Name	A. A. Lewis																
Attorney Docket Number	H0817.70003US00																
Sheet	31	of	34														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Jour. al, serial, symposium, catalog, etc.), date, page(s) , volume-issue number(s), publisher, city and/or country where published.	T ²
		SUN et al., Preconditioning of carbon monoxide releasing molecule-derived CO attenuates LPS-induced activation of HUVEC. Int J Biol Sci. 2008 Aug 22;4(5):270-8.	
		SUN et al., Role of CO-releasing molecules liberated CO in attenuating leukocytes sequestration and inflammatory responses in the lung of thermally injured mice. J Surg Res. 2007 May 1;139(1):128-35. Epub 2007 Feb 9.	
		SUZUKI et al., Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol. 2001 Dec;36(12):1301-6. Abstract only.	
		SZAKÁCS-SCHMIDT et al., Iron (II) thiolates as reversible carbon monoxide carriers. Inorg Chimica Acta. 1992;198-200:401-5.	
		SZALLASI et al., Dialdehyde sesquiterpenes and other terpenoids as vanilloids. Eur J Pharmacol. 1998 Aug 28;356(1):81-9. Abstract only.	
		TAILLÉ et al., Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. J Biol Chem. 2005 Jul 8;280(27):25350-60. Epub 2005 Apr 29.	
		TAKÁCS et al., Synthesis and molecular structure of carbonyl derivatives of Iron (II) thiolates containing nitrogen-donor ligands. Inorg Chimica Acta. 1989;166:39-46.	
		TAYEM et al., Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am J Physiol Renal Physiol. 2006 Apr;290(4):F789-94. Epub 2005 Nov 15.	
		TILG et al., Antitumour necrosis factor therapy in Crohn's disease. Expert Opin Biol Ther. 2002 Oct;2(7):715-21. Review. Abstract only.	
		TOMITA et al., Structure and reaction of bis(L-cysteinato)dicarbonyliron(II). Inorg Nucl Chem Lett. 1968;4:715-8.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	32	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TREICHEL et al., Synthesis and reactivity of bridging thiolato-manganese carbonyl complexes, <i>ET4[Mn2(μ-SR)3(CO)6]</i> , <i>J Organometal Chem.</i> 1985 Sept 10;292(3):385-93.	
		URBAN et al., Metal complexes of biologically important ligands, LXXXVII α-amino carboxylate complexes of palladium(II), iridium(III) and ruthenium (II) from chloro-bridged ortho-metallated metal compounds and [(OC)3Ru(CI)(μ-Cl)]2, <i>J Organomet Chem.</i> 1996;517:191-200.	
		URWYLER et al., Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. <i>Mol Pharmacol.</i> 2001 Nov;60(5):963-71.	
		VAN STAVEREN et al., Spectroscopic Properties, Electrochemistry, and Reactivity of Mo0, MoI, and MoII Complexes with the [Mo(bpa)(CO)3] Unit [bpa = bis(2-picoly)amine] and Their Application for the Labelling of Peptides. <i>Eur J Inorg Chem.</i> 2002;6:1518-29.	
		VANNACCI et al., Evaluation of the effects of a novel carbon monoxide releasing molecule (CORM-3) in an in vitro model of cardiovascular inflammation. 1. Histamine in allergy, inflammation, tissue growth and repair. <i>Inflamm Res.</i> 2006 Apr;55 Suppl 1:S05-6.	
		VANNACCI et al., The effect of a carbon monoxide-releasing molecule on the immunological activation of guinea-pig mast cells and human basophils. <i>Inflamm Res.</i> 2004;53 Suppl 53:S09-10.	
		VARADI et al., Beneficial effects of carbon monoxide-releasing molecules on post-ischemic myocardial recovery. <i>Life Sci.</i> 2007 Apr 3;80(17):1619-26. Epub 2007 Feb 2.	
		VERA et al., Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. <i>J Am Soc Nephrol.</i> 2005 Apr;16(4):950-8. Epub 2005 Feb 23.	
		VERONA et al., Regioselectivity in the nucleophilic functionalization of xanthene complexes of Mn(CO)3. <i>J Organomet Chem.</i> 1 Nov 1996;524(1-2):71-80.	
		VOLTI et al., Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. <i>Antiox Redox Signal.</i> May 2005;7(5-6):704-10.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
		Attorney Docket Number	H0817.70003US00
Sheet	33	of	34

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VREMAN et al., Determination of carbon monoxide (CO) in rodent tissue: effect of heme administration and environmental CO exposure. Anal Biochem. 2005 Jun 15;341(2):280-9. Abstract only.	
		WANG et al., A correlation of the visible and Soret spectra of dioxygen- and carbon monoxide-heme complexes and five-coordinate heme complexes with the spectra of oxy-, carboxy-, and deoxyhemoglobins. Biochemistry. 1979 Oct 30;18(22):4960-77.	
		WANG et al., Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001 May;280(5):H2321-8.	
		WANG et al., The chemical modification of KCa channels by carbon monoxide in vascular smooth muscle cells. J Biol Chem. 1997 Mar 28;272(13):8222-6.	
		WEIGEL et al., Inhibition of DNA replication in Escherichia coli by cyanide and carbon monoxide. J Biol Chem. 1975 Nov 10;250(21):8536-42.	
		WU et al., Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005 Dec;57(4):585-630. Review.	
		WU et al., Different mechanisms underlying the stimulation of K(Ca) channels by nitric oxide and carbon monoxide. J Clin Invest. 2002 Sep;110(5):691-700.	
		XI et al., Carbon monoxide activates KCa channels in newborn arteriole smooth muscle cells by increasing apparent Ca2+ sensitivity of alpha-subunits. Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H610-8. Epub 2003 Oct 16.	
		XU et al., A facile method for synthesis of (R)-(-) and (S)-(+)-homocitric acid lactones and related alpha-hydroxy dicarboxylic acids from D- or L-malic acid. Tetrahedron Lett. 30 May 2005;46(22):3815-18. Abstract only.	
		YACHIE et al., Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest. 1999 Jan;103(1):129-35.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/567,157-Conf. #4222
		Filing Date	June 1, 2006
		First Named Inventor	Roberto Angelo Motterlini
		Art Unit	1614
		Examiner Name	A. A. Lewis
Sheet	34	of	34
		Attorney Docket Number	H0817.70003US00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		YAN et al., Cytotoxicity of rhodium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor cells. Pharmazie. 2000 Apr;55(4):307-13.	
		ZHANG et al., Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3. J Biol Chem. 2003 Jan 10;278(2):1248-58. Epub 2002 Oct 23.	
		ZIMMERMAN et al., Cerebroprotective effects of the CO-releasing molecule CORM-A1 against seizure-induced neonatal vascular injury. Am J Physiol Heart Circ Physiol. Oct 2007;293:H2501-H2507.	
		ZUCKERBRAUN et al., Carbon monoxide protects against the development of experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G607-13. Epub 2005 May 12.	
		ZUCKERBRAUN et al., Carbon monoxide reverses established pulmonary hypertension. J Exp Med. 2006 Sep 4;203(9):2109-19. Epub 2006 Aug 14.	

Examiner Signature	/Amy Lewis/	Date Considered	09/28/2010
-----------------------	-------------	--------------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.